India is one of the most important emerging pharmaceutical markets, and the market is forecast to more than double between 2011 and 2017, growing at a compound annual growth rate of 16.1%.
Author: Anantharaman Kavassery Viswanathan and George Green
Publisher: Datamonitor Healthcare
Number of pages:12
India is one of the most important emerging pharmaceutical markets, and the market is forecast to more than double between 2011 and 2017, growing at a compound annual growth rate of 16.1%. Over-the-counter sales are set to undergo similarly rapid expansion.
Branded generics dominate and account for over 90% of the prescription market.
Table of Contents
4 EXECUTIVE SUMMARY
5 PHARMACEUTICAL MARKET SIZE AND SEGMENTATION
5 Retail market segment is dominant but the hospital segment has grown at a faster rate
5 The market is forecast to grow at around 16% out to 2017
6 Anti-infectives remain the bestselling therapy group
7 Leading brands in the Indian market
8 Economic growth will be the key market driver
9 Poor intellectual property protection is the key resistor for the patented market
9 The leading pharmaceutical companies in India
11 Pharmaceutical exports are a sizable and growing industry
List of Figures
5 Figure 1: Pharmaceutical market size ($bn), 2011–17
5 Figure 2: Pharmaceutical market size and forecast ($bn), 2011–17
List of Tables
6 Table 1: Indian pharmaceutical market, by therapy area ($m), 2011
8 Table 2: Top 10 brands in the Indian pharmaceutical market, 2011
9 Table 3: Market share of top 10 companies in the Indian pharma market, year to November
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.